In a randomized phase II trial, Fasching et al. compared the efficacy of paclitaxel and olaparib to paclitaxel/carboplatin followed by epirubicin/cyclophosphamide as a neoadjuvant treatment in patients with HER2-negative early BC and HRD (60.4% of patients were BRCA carriers, and the rest had a high HRD score based on the Myriad MyChoice HRD results). Here, ERBB2 is linked to breast cancer.